





RealRate

PHARMACEUTICAL 2020

Anixa Biosciences Inc Rank 299 of 358



The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Anixa Biosciences Inc is the variable Net Income, reducing the Economic Capital Ratio by 188% points.

The company's Economic Capital Ratio, given in the ranking table, is -91%, being 127% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	6,093
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,481
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,004
Other Liabilities	0
Other Net Income	71
Other Revenues	250
Property and Equipment	201
Research and Development	5,473
Selling, General and Administrative Expense	5,663

Output Variable	Value in 1000 USD
Assets	6,294
Liabilities	1,481
Expenses	12,140
Revenues	250
Stockholders Equity	4,812
Net Income	-11,819
Comprehensive Net Income	-11,819
Economic Capital Ratio	-91%